Anthracycline cardiotoxicity
Authors:
- Robin L JonesRJRobin L Jones
- Charles SwantonCSCharles Swanton
- Michael S EwerMEMichael S Ewer
- 18 October 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 5 (6) , 791-809
Abstract
The use of anthracyclines is limited by dose-dependent cardiotoxicity. Three forms of anthracycline cardiotoxicity are described; an immediate pericarditis-myocarditis syndrome, an early onset chronic progressive CHF developing during or shortly after therapy and late-onset cardiotoxicity presenting years following treatment. A number of risk factors have been reported, including; cumulative dose, administration schedule, mediastinal radiotherapy, old and young age, concurrent cardiovascular disease, combination therapy, gender, ethnicity and chromosomal abnormalities. Evaluation of left ventricular ejection fraction has been widely adopted as a means of monitoring and assessing anthracycline-induced cardiotoxicity. Biochemical markers and other techniques, such as endomyocardial biopsy, metaiodobenzylguanidine and indium-111-antimyosin scintigraphy are not routinely used. Methods employed to prevent cardiotoxicity include cumulative dose limitation, alteration of administration schedule, anthracycline analogues, liposomal formulations and the cardioprotective agent, dexrazoxane. With the growing number of paediatric malignancy survivors and the increasing use of anthracyclines in the adjuvant treatment of breast cancer, the cardiotoxicity associated with these agents will remain a formidable issue for physicians. Further work is required to identify patients at increased risk of cardiotoxicity and to develop novel methods of protecting and treating this adverse effect.Keywords
This publication has 182 references indexed in Scilit:
- N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?Clinical Chemistry, 2005
- DexrazoxaneDrugs, 2005
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to AnthracyclinesJournal of Clinical Oncology, 2004
- Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapyJACC, 2000
- Doxorubicin‐induced cardiomyopathy treated with carvedilolClinical Cardiology, 1998
- Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathyThe Lancet, 1996
- Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiationEuropean Journal of Cancer, 1996
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapyThe American Journal of Medicine, 1987
- Clinical and morphologic cardiac findings after anthracycline chemotherapyThe American Journal of Cardiology, 1983